Xin Yue, Zhang Bo, Zhao Junpeng, Liu Qianmei, Yin Haoyuan, Lu Qianjin
Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, Jiangsu, China.
Key Laboratory of Basic and Translational Research on Immune-Mediated Skin Diseases, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China.
Expert Opin Drug Discov. 2022 May;17(5):489-500. doi: 10.1080/17460441.2022.2050691. Epub 2022 Mar 14.
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with substantial phenotypic heterogeneity. Currently, our understanding of the pathogenesis is still limited, and as a result, specific and efficacious therapies are lacking. Various mouse models have been established to serve as powerful tools that will promote a better understanding of the disease and the ability to test novel drugs before clinical application.
The authors review the existing mouse models of SLE in terms of pathogenesis and manifestations, as well as their applications in drug discovery and development. The areas of focus include promising novel therapeutics that could benefit patients in the future and the contribution of mouse models used in preclinical studies.
Given the diversity of SLE mouse models with different characteristics, researchers must select a suitable model based on the mechanism involved. The use of multiple models is needed for drug testing studies to evaluate drug efficacy on different genetic backgrounds and other mechanisms to provide a reference for clinical trials.
系统性红斑狼疮（SLE）是一种具有显著表型异质性的多系统自身免疫性疾病。目前，我们对其发病机制的理解仍然有限，因此缺乏特异性且有效的治疗方法。已经建立了各种小鼠模型，作为强大的工具，有助于更好地理解该疾病，并在临床应用前测试新药。
作者从发病机制、表现以及在药物发现与开发中的应用等方面对现有的SLE小鼠模型进行了综述。重点关注的领域包括未来可能使患者受益的有前景的新型疗法，以及临床前研究中使用的小鼠模型的贡献。
鉴于具有不同特征的SLE小鼠模型的多样性，研究人员必须根据所涉及的机制选择合适的模型。药物测试研究需要使用多种模型，以评估药物在不同遗传背景和其他机制上的疗效，为临床试验提供参考。
